What is the primary purpose of this 10-Q filing?

This 10-Q filing provides a comprehensive update on Merck & Co., Inc.'s financial performance and condition for the first quarter ended March 30, 2004. It includes interim financial statements, management's analysis of the results, and other relevant business and legal disclosures.

What key financial areas should investors focus on in this report?

Investors should focus on the 'Statements of Consolidated Operations' for revenue and profitability trends, the 'Consolidated Balance Sheets' for the company's asset and liability structure, and the 'Statements of Consolidated Cash Flows' to understand cash generation and usage. Management's Discussion and Analysis (MD&A) will offer crucial commentary on these figures.

Are there any significant legal matters disclosed in this filing?

Item 1 of Part II, 'Legal Proceedings,' indicates that there are legal matters that shareholders should be aware of. The specifics of these proceedings would need to be reviewed within the body of the filing for detailed information.

What does the inclusion of 'Exhibits' like Section 302 certifications signify?

The inclusion of exhibits such as Section 302 certifications (related to Sarbanes-Oxley Act) signifies the company's commitment to internal controls and financial reporting integrity. These certifications are made by the principal executive and financial officers regarding the accuracy of financial reports.

MRK 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. reported its first quarter results for the period ending March 30, 2004. The company's performance in this quarter reflects its ongoing strategic initiatives and the evolving pharmaceutical market landscape. Investors should pay close attention to revenue trends, particularly from key products, and the company's progress in its research and development pipeline, which is crucial for future growth. The financial statements and management's discussion offer insights into the company's operational efficiency and its ability to manage expenses while investing in innovation.

Key Highlights

1The filing covers the financial performance of Merck & Co., Inc. for the quarter ended March 30, 2004.
2Key financial statements including Consolidated Operations, Balance Sheets, and Cash Flows are presented.
3Management's Discussion and Analysis of Financial Condition and Results of Operations provides context for the financial results.
4The report includes details on Legal Proceedings and submission of matters to security holders.
5Exhibits include the computation of the ratio of earnings, an awareness letter, and Section 302 certifications, indicating a focus on compliance and financial reporting accuracy.
6This 10-Q filing provides a snapshot of Merck's financial health and operational performance during the first quarter of 2004.

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions